An NBC News article, “French authorities call for ban of Allergan textured breast implants” provides us with recent data on this issue. The number of BIA-ALCL diagnoses has gone from one per million to one per 2,832. The total number of cases now is 457 in the U.S. and approximately 700 worldwide. The number of deaths has risen from 9 to 16.
The February 2019 NBC News article informs that in the beginning of February, France banned Allergan’s textured breast implants. 85% of the French market comes from textured breast implants, but they have become too increasingly associated with BIA-ALCL. The ban was put in place two days after the FDA’s public investigatory hearing regarding the health risks surrounding breast implant devices. You can refer to our recent article from early April, “March 2019 FDA Meeting On Breast Implants: A Summary Of What You Need To Know” for a concise version of what took place at the meeting.
We learn from the ICIJ article, “Canada Halts Sales of Cancer-Linked Breast Implants, as Global Scrutiny Grows” that now two more countries, Canada and the Netherlands, are following France’s decision.
This Allergan textured breast implants lymphoma cancer issue is evidently becoming increasingly troublesome in the United States and other countries around the world. As always, we will continue to monitor new information and developments in the BIA-ALCL literature, and watch to see if the U.S. may follow in the decision to ban textured implants.[Read article in full at original source]
Written by: Laura Beasley, Legal Assistant
Law Offices of Thomas J. Lamb, P.A.
Strictly Confidential, No Obligation.